Posted on June 26, 2015 by MANA BMS Continues Transforming into Specialty Pharma June 26, 2015, 03:06:31 AM Bristol-Myers Squibb continues its journey towards becoming a highly focused specialty pharmaceutical company. In FierceBiotech this morning, there is a story about plans for BMS to build a consolidated presence in the biotech hotspot of Kendall Square in Cambridge, MA. As part of the industry’s efforts to boost R&D productivity, BMS is planning to locate around 300 researchers in the new facility to “…focus on genetically defined diseases, molecular discovery technologies and discovery platform chemistry,” according to the article in FierceBiotech. As part of this consolidation, the company is shutting down facilities in Waltham, MA and Wallingford, CT, and laying off approximately 100 people from its R&D operations. But what really caught my attention is the news that BMS will be terminating it’s virology R&D program so the company can focus on genetically driven rare diseases and immunoscience–particularly cancer immunotherapy. According to MedCity News, this reshuffle will mainly impact the company’s early work in hepatitis B and HIV therapies, though it won’t affect the virology therapies currently in development or on the market. At a time when biotech and pharma M&A activity is red hot, and companies seem to be focused on growth at all costs, BMS seems to be pursuing a more deliberate and focused strategy to become the world’s most successful specialty pharmaceutical company, and sticking to those areas where it has historically had the most success.